Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cell Cycle

• Publication date

  2013-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.23372PMID 23324350PMCID PMC3587450
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin selectively affects human glioblastoma tumor-initiating cell viability

  2013cited by this paper
• A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.

  2013cited by this paper
• High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells

  2012cited by this paper
• Molecular mechanisms of sorafenib action in liver cancer cells

  2012cited by this paper
• MCL1 down‐regulation plays a critical role in mediating the higher anti‐leukaemic activity of the multi‐kinase inhibitor Sorafenib with respect to Dasatinib

  2012cited by this paper
• The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.

  2012cited by this paper
• Concise Review: Cancer Stem Cells and Minimal Residual Disease

  2012cited by this paper
• Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma

  2012cited by this paper
• Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide

  2012cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• Heterogeneity maintenance in glioblastoma: a social network.

  2011cited by this paper
• Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.

  2011cited by this paper
• The NFκB pathway: a therapeutic target in glioblastoma

  2011cited by this paper
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

  2011cited by this paper
• Pathway inhibition: emerging molecular targets for treating glioblastoma.

  2011cited by this paper
• Akt signaling is required for glioblastoma maintenance in vivo.

  2011cited by this paper
• Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges.

  2011cited by this paper
• Invasive glioblastoma cells acquire stemness and increased Akt activation.

  2010cited by this paper
• Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.

  2010cited by this paper
• Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation

  2010cited by this paper
• Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

  2010cited by this paper
• Sorafenib exerts anti-glioma activity in vitro and in vivo.

  2010cited by this paper
• Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3

  2010cited by this paper
• Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors*

  2009cited by this paper
• STAT3 regulation of glioblastoma pathogenesis.

  2009cited by this paper
• Sorafenib for the treatment of unresectable hepatocellular carcinoma.

  2009cited by this paper
• SOX2 Silencing in Glioblastoma Tumor‐Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

  2009cited by this paper
• Molecular Cancer BioMed Central

  2008cited by this paper
• Constitutive activation of Raf-1 induces glioma formation in mice.

  2008cited by this paper
• Sorafenib for the treatment of unresectable hepatocellular carcinoma

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

  2007cited by this paper
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.

  2007cited by this paper
• Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas

  2006cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

  2006cited by this paper
• Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

  2006cited by this paper
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006cited by this paper
• Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

  2006cited by this paper
• Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

  2006cited by this paper
• Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.

  2005cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• Identification of a cancer stem cell in human brain tumors.

  2003cited by this paper
• Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

  2001cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice

  2000cited by this paper
• The classification of tumours of the central nervous system.

  1982cited by this paper

• A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

  2025cites this paper
• Sorafenib Alters Interstitial Proton and Sodium Levels in the Tumor Microenvironment: A 1H/23Na Spectroscopic Imaging Study

  2025cites this paper
• Expression of calpastatin hcast 3-25 and activity of the calpain/calpastatin system in human glioblastoma stem cells: possible involvement of hcast 3-25 in cell differentiation

  2024cites this paper
• Understanding the Role of Endothelial Cells in Glioblastoma: Mechanisms and Novel Treatments

  2024cites this paper
• Glioma Stem Cells as Promoter of Glioma Progression: A Systematic Review of Molecular Pathways and Targeted Therapies

  2024cites this paper
• Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets

  2024cites this paper
• The expression of pro-prion, a transmembrane isoform of the prion protein, leads to the constitutive activation of the canonical Wnt/β-catenin pathway to sustain the stem-like phenotype of human glioblastoma cells

  2024cites this paper
• Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?

  2023cites this paper
• Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

  2023cites this paper
• Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles

  2022cites this paper
• Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

  2022cites this paper
• Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives

  2022cites this paper
• The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma

  2021cites this paper
• Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy

  2021cites this paper
• Therapeutic approaches to overcome temozolomide resistance in glioblastoma

  2021cites this paper
• Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies

  2020cites this paper
• Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond

  2020cites this paper
• Autophagy as a Potential Therapy for Malignant Glioma

  2020cites this paper
• 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma.

  2019cites this paper
• Identification of KLRC2 as a candidate marker for brain tumor-initiating cells

  2019cites this paper
• αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion

  2019cites this paper
• Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity

  2019cites this paper
• Amentoflavone Effectively Blocked the Tumor Progression of Glioblastoma via Suppression of ERK/NF- κ B Signaling Pathway.

  2019cites this paper
• Mcl‐1 targeting could be an intriguing perspective to cure cancer

  2018cites this paper
• Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability

  2018cites this paper
• Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells

  2018cites this paper
• An RGD small-molecule integrin antagonist induces detachment-mediated anoikis in glioma cancer stem cells.

  2018cites this paper
• Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

  2018cites this paper
• Novel therapies hijack the blood–brain barrier to eradicate glioblastoma cancer stem cells

  2018cites this paper
• Translational gap in ongoing clinical trials for glioma.

  2018cites this paper
• Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.

  2018cites this paper
• In vitro and in vivo characterization of stem‐like cells from canine osteosarcoma and assessment of drug sensitivity

  2018cites this paper
• Targeting the perivascular niche in brain tumors

  2018cites this paper
• Structural evidence of quercetin multi‐target bioactivity: A reverse virtual screening strategy

  2017cites this paper
• Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.

  2017cites this paper
• Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas

  2017cites this paper
• Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?

  2017cites this paper
• The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

  2017cites this paper
• Updates in Genetic Molecular Targeted Therapy for Glioblastoma

  2016cites this paper
• Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells

  2016cites this paper
• Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines

  2016cites this paper
• Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells

  2016cites this paper
• Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma

  2016cites this paper
• Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.

  2016cites this paper
• NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling.

  2016cites this paper
• Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737

  2016cites this paper
• Cancer stem cells and chemoresistance: The smartest survives the raid.

  2016cites this paper
• Small-Molecule Inhibitors in Glioblastoma: Key Pathways and Resistance Mechanisms

  2016cites this paper
• Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.

  2016cites this paper
• Development of targeted therapies in treatment of glioblastoma

  2015cites this paper
• In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors

  2015cites this paper
• TRIM8 downregulation in glioma affects cell proliferation and it is associated with patients survival

  2015cites this paper
• The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence

  2015cites this paper
• Characterization of cellular and molecular responses of human gliobastoma to transforming growth factor-b signalling pathway inhibition

  2015cites this paper
• Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.

  2015cites this paper
• The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

  2015cites this paper
• Harnessing the apoptotic programs in cancer stem‐like cells

  2015cites this paper
• Hexane extract from Sargassum serratifolium inhibits the cell proliferation and metastatic ability of human glioblastoma U87MG cells.

  2015cites this paper
• CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment

  2014cites this paper
• The role of STAT3 signaling in mediating tumor resistance to cancer therapy.

  2014cites this paper
• Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current

  2014cites this paper
• ABC transporters as differentiation markers in glioblastoma cells

  2014cites this paper
• Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells.

  2014influential citation
• Getting to the Source: Selective Drug Targeting of Cancer Stem Cells

  2014cites this paper
• Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness

  2014cites this paper
• New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells

  2014cites this paper
• MicroRNAs in Stem Cells and Cancer Stem Cells

  2014cites this paper
• Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.

  2013influential citation
• Therapeutic strategies targeting glioblastoma stem cells.

  2013cites this paper
• Chemical approaches to targeting drug resistance in cancer stem cells.

  2013cites this paper
• High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma

  2013cites this paper
• Current World Literature

  2013cites this paper
• Oncotargets and Therapy Dovepress Combining Molecular Targeted Agents with Radiation Therapy for Malignant Gliomas

  year unknowncites this paper
• and in vivo characterization of stem-like cells from canine vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity

  year unknowncites this paper